Showing results (451-460 of 573) with videos related to

Sort By:
Pageof 58
JAMA Oncology|April 6, 2023
Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer: The EXTEND Phase 2 Randomized Clinical TrialChad Tang, Alexander D Sherry, Cara Haymaker, et al.
The Lancet. Oncology|October 30, 2016
Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 studyDaniel R Gomez, George R Blumenschein, J Jack Lee, et al.
The Lancet. Oncology|February 5, 2026
Metastasis-directed therapy and standard of care versus standard of care for oligometastatic prostate cancer (WOLVERINE): a systematic review and individual patient data meta-analysis from the X-MET collaborationChad Tang, Alex D Sherry, Hyunsoo Hwang, et al.
ACS Infectious Diseases|December 22, 2020
Therapeutic Potential of Nitazoxanide: An Appropriate Choice for Repurposing versus SARS-CoV-2?Andrew V Stachulski, Joshua Taujanskas, Sophie L Pate, et al.
Oncology|June 24, 2019
A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid TumorsDavid Hong, Drew Rasco, Michael Veeder, et al.
Oncotarget|April 22, 2017
Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancerZhijie Wang, Sarina Piha-Paul, Filip Janku, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 6, 2016
Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced CancerDavid Hong, Jeffrey Infante, Filip Janku, et al.
Molecular Cancer Therapeutics|September 26, 2014
Triple-negative breast cancer patients treated at MD Anderson Cancer Center in phase I trials: improved outcomes with combination chemotherapy and targeted agentsPrasanth Ganesan, Stacy Moulder, J Jack Lee, et al.
JACC. Cardiovascular Interventions|March 27, 2024
Prognostic Implications of Microvascular Resistance Reserve in Symptomatic Patients With Intermediate Coronary StenosisSeung Hun Lee, Ki Hong Choi, David Hong, et al.
Oncotarget|May 6, 2016
Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experienceMing-Mo Hou, Zhijie Wang, Filip Janku, et al.
Pageof 58